Dáil Éireann Debate, Thursday - 28 September 2023
266. Deputy Richard O'Donoghue asked the Minister for Health when the rapid HTA, undertaken by HIQA in November 2022, reviewing the evidence of the clinical and cost-effectiveness of continuous and intermittent glucose monitoring systems for people with type 1 diabetes, will be published; and if it recommends the widening of access to these devices, if funding will be provided. [41956/23]
View answerThe Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement under the community schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
In making a relevant reimbursement decision, the HSE is required under the Act to have regard to a number of criteria including clinical efficacy, the health needs of the public, cost effectiveness and potential or actual budget impact. I, as the Minister for Health, have no role in these decisions.
The Health Information and Quality Authority have undertaken a Health Technology Assessment (HTA) in respect of the provision of glucose monitoring devices to adults with Type I diabetes. It is expected that this will be published soon. This HTA will inform the HSE decision-making process.
While preparations in respect of Budget 2024 are ongoing, any health measures introduced will be in the context of the implementation of the health commitments in the Programme for Government and the funding available to progress healthcare priorities.
